Free Trial

Insmed Q4 2023 Earnings Report

Insmed logo
$70.44 +1.03 (+1.48%)
(As of 12/20/2024 05:31 PM ET)

Insmed EPS Results

Actual EPS
-$1.28
Consensus EPS
-$1.13
Beat/Miss
Missed by -$0.15
One Year Ago EPS
-$1.20

Insmed Revenue Results

Actual Revenue
$83.70 million
Expected Revenue
$82.15 million
Beat/Miss
Beat by +$1.55 million
YoY Revenue Growth
+41.10%

Insmed Announcement Details

Quarter
Q4 2023
Time
Before Market Opens

Conference Call Resources

URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)

Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.

>> Register for the Workshop Now

Insmed Earnings Headlines

Should You Invest in Insmed Incorporated (INSM)?
URGENT: This Altcoin Opportunity Won’t Wait – Act Now
Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.
See More Insmed Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Insmed? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Insmed and other key companies, straight to your email.

About Insmed

Insmed (NASDAQ:INSM) is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

View Insmed Profile

More Earnings Resources from MarketBeat

Upcoming Earnings